<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neuro Oncol</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuro-oncology</journal-id>
<journal-id journal-id-type="publisher-id">neuonc</journal-id>
<journal-id journal-id-type="hwp">neuonc</journal-id>
<journal-title-group>
<journal-title>Neuro-Oncology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1522-8517</issn>
<issn pub-type="epub">1523-5866</issn>
<publisher>
<publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26851632</article-id>
<article-id pub-id-type="pmc">4827037</article-id>
<article-id pub-id-type="doi">10.1093/neuonc/nov200</article-id>
<article-id pub-id-type="publisher-id">nov200</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Invited Reviews</subject>
</subj-group>
<series-title>Editor's choice</series-title>
</article-categories>
<title-group>
<article-title>Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Blakeley</surname>
<given-names>Jaishri O.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Plotkin</surname>
<given-names>Scott R.</given-names>
</name>
</contrib>
<aff><addr-line>Neurology, Neurosurgery and Oncology</addr-line>, <institution>Johns Hopkins University</institution>, <addr-line>Baltimore, MD</addr-line> (J.O.B.); <addr-line>Neurology, Harvard Medical School, Stephen E. and Catherine Pappas Center for Neuro-Oncology</addr-line>, <institution>Massachusetts General Hospital</institution>, <addr-line>Boston, MA</addr-line> (S.R.P.)</aff>
</contrib-group>
<author-notes>
<corresp><bold>Corresponding Author</bold>: Jaishri Blakeley, MD, Johns Hopkins University, Associate Professor of Neurology, Neurosurgery and Oncology, 1550 Orleans Street, Suite IM16, Baltimore, MD 21287 (<email>jblakel3@jhmi.edu</email>).</corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>5</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>06</day>
<month>2</month>
<year>2016</year>
</pub-date>
<volume>18</volume>
<issue>5</issue>
<fpage>624</fpage>
<lpage>638</lpage>
<history>
<date date-type="received">
<day>8</day>
<month>5</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>8</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>Â© The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="nov200.pdf"></self-uri>
<abstract>
<p>Neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN) are tumor-suppressor syndromes. Each syndrome is an orphan disease; however, the tumors that arise within them represent the most common tumors of the nervous system worldwide. Systematic investigation of the pathways impacted by the loss of function of neurofibromin (encoded by <italic>NF1</italic>) and merlin (encoded by <italic>NF2</italic>) have led to therapeutic advances for patients with NF1 and NF2. In the syndrome of SWN, the genetic landscape is more complex, with 2 known causative genes (<italic>SMARCB1</italic> and <italic>LZTR1</italic>) accounting for up to 50% of familial SWN patients. The understanding of the molecular underpinnings of these syndromes is developing rapidly and offers more therapeutic options for the patients. In addition, common sporadic cancers harbor somatic alterations in <italic>NF1</italic> (ie, glioblastoma, breast cancer, melanoma), <italic>NF2</italic> (ie, meningioma, mesothelioma) and <italic>SMARCB1</italic> (ie, atypical teratoid/rhabdoid tumors) such that advances in management of syndromic tumors may benefit patients both with and without germline mutations. In this review, we discuss the clinical and genetic features of NF1, NF2 and SWN, the therapeutic advances for the tumors that arise within these syndromes and the interaction between these rare tumor syndromes and the common tumors that share these mutations.</p>
</abstract>
<kwd-group>
<kwd>NF1</kwd>
<kwd>NF2</kwd>
<kwd>schwannomatosis</kwd>
<kwd>therapeutics</kwd>
<kwd>tumor suppressor syndrome</kwd>
</kwd-group>
<funding-group>
<award-group id="funding-1">
<funding-source>the Neurofibromatosis Therapeutic Acceleration Program</funding-source>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>